Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Weight Gain 1Overweight 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sucrose × Endocrine × Clear all
NCT04804397 2021-03-18

Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

University of Hull

Phase NA Completed
80 enrolled
Endocrine

Weight Gain, Multiple Endocrine Neoplasia Type 1, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡